| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e019980e0d3964666d42b84f16f7fe2a |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-737
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-726
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-38 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-726
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-737 |
| filingDate |
1995-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3690fabc0aab4cf20c27190fd5962050
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b759e35f20be6c9597fd7bd925ca2303
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79cdbd52c1ff6aeda7e6eeb5a84e2151
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9f271b6ae4e5179edfcd4b2f45ffc5e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2773a0461a99514f60140682169ef74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f15c914f35a87db9ae36725e2c9f8bba |
| publicationDate |
1996-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0710483-A1 |
| titleOfInvention |
Use of some glycosaminoglycans for the manufacture of a medicament for the treatment of chronic renal failure |
| abstract |
The use of some glycosaminoglycans like sulodexide, low molecular weight heparin and low molecular weight dermatan sulfate and of the medicines by parenteral use that contain them in the treatment of patients suffering from chronic renal insufficiency subjected to peritoneal dialysis is the object of the present invention. n The effectiveness of this use has been shown both by pharmacological studies carried out in nephrectomized rats to whom a peritoneal damage has been caused and by clinical studies carried out in patients suffering from chronic renal insufficiency subjected to CAPD and treated by intraperitoneal route (i.p.) with 2 ml vials of VESSEL DUE F® containing 50 mg of sulodexide. n A significant increase of the peritoneal transports of urea and of creatinine joined to a significant decrease of the protein-loss in the peritoneal effluent has been observed. Significant changes of the ultrafiltration capacity and of haemorrhagic-coagulative complications have not been observed during the study. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1016410-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03011305-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0104632-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0220091-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009044765-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7259152-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03002129-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007079338-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02100417-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007079338-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009121959-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0220091-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02100417-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2002304265-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9149572-B2 |
| priorityDate |
1994-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |